Skip to main content
. 2018 Sep 11;9(9):930. doi: 10.1038/s41419-018-0952-8

Fig. 5. The mechanism of cisplatin sensitization upon MAPKi-resistance acquisition in metastatic melanoma cells.

Fig. 5

The level of TAp73α negatively influences the sensitivity towards cisplatin and carboplatin treatment by regulation of NER in melanoma cells. A subset of MAPKi-resistant melanoma cells have a reduced level of TAp73α and are thereby sensitive to apoptosis induction mediated by platinum-based drug treatments